Answers are grounded in this paper and cite their sources.
This study was aimed at evaluating the role of antiretroviral drug monitoring, viral load, and CD4 counts amongst HIV-1 infected individuals in FMC, Lokoja, Nigeria, that randomly recruited 154 participants within the age range of 18 and 65 years with a population- based sample of males and females divided into three groups designated A to C; comprising of 40 HIV-1 seropositive individuals on HAART (TDF + 3TC + EFV) designated as group A, 35 HIV-1 seropositive individuals on HAART (AZT + 3TC +NVP) designated as group B, and 79 HAART naïve HIV-1 seropositive individuals designated as control group C. Two points blood samples were taken for group A and group B participants for the measurement of drugs(HAART) using HPLC, HIV-1 RNA Load using PCR and CD4 counts using flow cytometry while one point samples were taken for group C for the measurement of HIV-1 RNA Load and CD4 counts. Data were expressed as mean ± standard deviation and Chi-square analysis. The results showed a significant difference in HIV-1 RNA Load and CD4 counts in group A when compared to group B and group C (p<0.05). There was also a significant difference in HIV-1 RNA Load and CD4 counts in group B when compared with group C (p<0.05). Plasma drug concentrations were higher at 12 months of therapy when compared with plasma drug concentrations at 6 months (p<0.05) with 17.4% virologic failure in participants on nevirapine based regimen and 7.5% virologic failure amongst participants on efavirenz based regimen; this showed the superiority efficacy of efavirenz based regimen to nevirapine based regimen.
No takes yet. Share an insight, caveat, or question.
Isaac et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: